It's the first drug shown to slow Alzheimer's. Why is is it off to a slow start?
Time:2024-05-21 18:35:56 Source:healthViews(143)
The first drug shown to slow Alzheimer’s disease hit the U.S. market over a year ago, but sales have lagged, major hospital systems have taken months to start using it and some insurers have rejected coverage.
Doctors also expect some patients will hesitate to take Leqembi due to its limited impact and potential side effects. They say it will take years to learn how best to deploy the drug and that work must be done to improve diagnosis.
“This is the start of a very exciting journey,” said Dr. Ambar Kulshreshtha, a suburban Atlanta family physician focused on dementia patients.
More than 6 million Americans, and millions more worldwide, have Alzheimer’s disease, the most common cause of dementia. There’s no cure, but Leqembi clears a sticky brain protein called amyloid that’s a key indicator of Alzheimer’s.
Studies showed that it can delay the progression of the disease by a few months when given to people with mild symptoms. Some experts say the delay may be too subtle for patients to notice.
Previous:Travis Kelce downs whiskey shot on slice of bread at Kelce Jam without Taylor Swift
Next:Iran helicopter crash that killed President Raisi could reverberate across the Middle East
You may also like
- Kosovo prepares a new draft law on renting prison cells to Denmark after the first proposal failed
- Marte's 3
- Toronto's Nylander out for Game 1 against Bruins
- Tomas Totland scores first MLS goal in stoppage time, St. Louis plays Sporting KC to 3
- The fightback begins: Boss of London's Queen Mary University tells pro
- Josie Gibson voices fears over having her heart broken AGAIN amid string of romantic disasters
- Helen Maroulis becomes first US female wrestler to qualify for three Olympic teams
- Simon Cowell reveals why he wears red
- Medics remove 150 MAGGOTS from a woman's mouth after dental procedure left her with rotting tissue